Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
Kaposi's sarcoma in Zaire.
IARC Sci Publ. 1984;(63):549-57. Unique Identifier : AIDSLINE MED/85259973 Gigase PL; de Muynck A; de Feyter M
Abstract:
Kaposi's sarcoma (KS) was recognized in 1948 in Zaire, where it has probably always been endemic. In 1957 a relative frequency of KS of 9% of all biopsied cancers was found. There are fluctuations in incidence within the country, with a higher incidence in the east, where it was estimated in 1960 at about 5-10 cases per 100 000 per year in males, with a relative frequency of 14% of all malignant male tumours and a M/F ratio higher than 10/1. More recently KS accounted for roughly 17% in males and 2% in females of all malignant biopsied tumours in north-east Zaire (1969-1983). In 2 years (1982-1983), 26 male and 5 female KS cases were histologically confirmed in an area of eastern Zaire with a population of roughly 300 000 people. It has been suggested, on the basis of this high incidence of KS and of the recent identification of African AIDS cases, that the hypothetical transmissible agent in AIDS might originate from Central Africa. The frequency of KS in African AIDS cases was low (16%) as compared to that in the USA. The M/F ratio of AIDS was 6/4 and that of AIDS-associated KS 1/1. AIDS-associated cases occurred in young adults and were generalized and fulminating. African KS occurs at a younger modal age than in Caucasians, which is the combined result of increasing incidence with age and of the high proportion of young people in the population in Africa but not of a higher risk for younger male adults, as in AIDS.(ABSTRACT TRUNCATED AT 250 WORDS)
Keywords: Adolescence Adult Aged Child Child, Preschool Female Human Male Middle Age Sarcoma, Kaposi's/*EPIDEMIOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Zaire JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
